Stakeholder assessment of the evidence for cancer genomic tests

Genomic Testing for Screening or Disease Risk Prediction

4 The accompanying evidence review focused on BRCA-related breast and ovarian cancer only; it did ... The Key Informants represented the following stakeholder ...

From public health genomics to precision public health: a 20-year ...

meeting;10 Stakeholder assessment of the evidence for cancer genomic tests11. Function 2: Assurance. Assuring that genetic information is used.

Proposed Medicare Coverage Criteria for Cancer Genetic Tests ...

The draft LCDs "include only an evaluation of the knowledgebases whose sponsors presumably have considered evidence regarding genetic testing," ...

Next Generation Sequencing (NGS) for Medicare Beneficiaries with ...

... genomic testing and cell-free DNA in ... Since our evidence question and analytic framework apply to molecular diagnostic tests for advanced cancer ...

ACMG Documents in Development

Stakeholders Assessing Genetics with Employers (SAGE), a federally funded research ... genetic and genomic testing. Workgroup Members. Heidi Rehm (Co-chair) ...

Population Genomic Screening for Three Common Hereditary ...

Population genomic screening using clinical sequencing with a restricted panel of high-evidence genes, cascade testing of first-degree relatives ...

Genomics in Scotland strategy: equality impact assessment - gov.scot

Genomic testing is used to support diagnosis, clinical management, and treatment decisions across a growing number of clinical specialities, ...

Published Articles - Resource Center | CMTP

... Stakeholder-informed Prioritization of Cancer Genomics Research (Feb 2013) ... 12.25. Stakeholder Assessment of the Evidence for Cancer Genomic Tests: Insights ...

Evaluating genetic and genomic tests for heritable conditions in ...

Assessment occurs after the national regulatory authority has approved the technology for marketing. One of these HTA committees, the Medical ...

Stakeholders' Interest and Attitudes toward Genomic Medicine and ...

Various stakeholders were identified by experts in the field of epidemiology, genomic medicine and pharmacogenomics, and public health. The ...

Building the evidence base for decision making in cancer genomic ...

Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies · Medicine. Genetics in Medicine · 2012.

Value-based genomics - Oncotarget

Evidence suggests that single-gene tests are best served in clinical ... Genomic analysis of plasma cell-free DNA in patients with cancer.

ASCO Releases Updated Policy Statement on Genetic and Genomic ...

ASCO issued an updated policy statement on genetic and genomic testing for cancer susceptibility. Published in the Journal of Clinical ...

Katrina A.B. Goddard, PhD

Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genet. Med 2012 Jul;14(7):656-62. PMCID: PMC4437504. 72 ...

P663: A community based participatory research pilot project to ...

stakeholders to remain current on the most salient literature to make unbiased, informed, evidence-based decisions on genetic and genomic tests. https://doi ...

HOPE-Genomics: Empowering Cancer Patients through Innovations ...

Early evidence reveals that despite rapid adoption of genomic testing in ... assess stakeholder attitudes toward, and the quality of ...

Genomic testing in voluntary workplace wellness programs in the ...

Our research found little evidence of broad uptake of wGT among US companies, though information gathering was challenging.

joint report of the council on medical service and the council on

... evidence are currently used to assess genetic/genomic tests, and some ... stakeholders to support regulatory reform for genetic tests that ...

Evaluating the Clinical Utility of Genomic Variants Derived from Next ...

The clinical utility of genomic tests has been assessed as the balance of benefits and harms (Teutsch et al., 2009) for the use of the test in ...

the ESMO Scale for Clinical Actionability of molecular Targets ...

The ESCAT aims to define clinical evidence-based criteria to prioritise cancer genomic abnormalities as markers to select patients for targeted therapies.